MSU
MNTA

Maple Securities USA’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Maple Securities USA’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,683
Closed -$154K – 533
2013
Q3 		$154K Buy
+10,683
New +$164K 0.01% 386

Other funds holding MNTA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Maple Securities USA's MNTA Position: Q4 2013 in Review

Maple Securities USA sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2013, closing a stake of 10,683 shares — an estimated $154K sold.

Maple Securities USA first reported a position in MNTA in Q3 2013 and held it in 1 quarter. The position peaked at $154K in Q3 2013. 133 funds tracked by Wall St. Rank hold MNTA as of Q4 2013.

  • Maple Securities USA reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Maple Securities USA sold 10,683 Momenta Pharmaceuticals, Inc. shares in Q4 2013, an estimated $154K.
  • Maple Securities USA first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • Maple Securities USA's Momenta Pharmaceuticals, Inc. position peaked at $154K in Q3 2013.
  • 133 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2013.

Based on Maple Securities USA's 13F filing for Q4 2013, filed 5 Feb 2014.